Submission of a BLA for atacicept in IgAN to the U.S. FDA in Q4 2025 for accelerated approval; potential commercial launch in 2026; Presentation of the full 36-week results from the pivotal ORIGIN 3 trial expected at a medical congress in Q4 2025; Initial results from the PIONEER Phase 2 basket trial expected in Q4 2025; Pivotal ORIGIN 3 study expected to be completed in 2027
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Tesla grants Musk big payout, Wayfair reports Q2 beat: Morning Buzz
- Coinbase downgraded, Spotify upgraded: Wall Street’s top analyst calls
- Vera Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
- Millions in Insider Buying Point to These 2 Stocks — Here’s What It Could Signal
- Vera Therapeutics Inc put volume heavy and directionally bearish